Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.

Isla, Dolores; De Castro, Javier; Juan, Oscar; Grau, Santiago; Orofino, Javier; Gordo, Rocío; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío

Isla, Dolores; De Castro, Javier; Juan, Oscar; Grau, Santiago; Orofino, Javier; Gordo, Rocío; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío.

Afiliação

Isla D; Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza.
De Castro J; Medical Oncology Department, Universitary Hospital La Paz, Madrid.
Juan O; Medical Oncology Department, Universitary and Polytechnic Hospital La Fe, Valencia.
Grau S; Pharmacy Department, Del Mar Hospital, Barcelona.
Orofino J; Roche Farma, S.A., Health Economics.
Gordo R; Roche Farma, S.A., Health Economics.
Rubio-Terrés C; Health Value, Health Economics, Madrid, Spain.
Rubio-Rodríguez D; Health Value, Health Economics, Madrid, Spain.

Clinicoecon Outcomes Res ; 9: 31-38, 2017.

Article em En | MEDLINE | ID: mdl-28115857

Palavras-chave

adverse event; afatinib; cost analysis; erlotinib; non-small cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google